386 related articles for article (PubMed ID: 29175080)
1. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
2. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
3. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
4. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
[TBL] [Abstract][Full Text] [Related]
5. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
6. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
Sun S; Zhao S; Yang Q; Wang W; Cai E; Wen Y; Yu L; Wang Z; Cai J
Cancer Sci; 2018 Jun; 109(6):1853-1864. PubMed ID: 29630768
[TBL] [Abstract][Full Text] [Related]
8. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
9. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
10. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
Min Y; Li J; Liu F; Yeow EK; Xing B
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
[TBL] [Abstract][Full Text] [Related]
11. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract][Full Text] [Related]
13. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
14. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
15. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
16. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
17. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
18. Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.
Zhao Y; Woods JA; Farrer NJ; Robinson KS; Pracharova J; Kasparkova J; Novakova O; Li H; Salassa L; Pizarro AM; Clarkson GJ; Song L; Brabec V; Sadler PJ
Chemistry; 2013 Jul; 19(29):9578-91. PubMed ID: 23733242
[TBL] [Abstract][Full Text] [Related]
19. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
20. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
Kang X; Wang Y; Chen Z; Wu Y; Chen H; Yang X; Yu C
Chem Commun (Camb); 2020 Sep; 56(76):11271-11274. PubMed ID: 32830841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]